NCT04191616 · REGISTRY CONDITION SEARCH

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2025-09-04

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC)

→

outcome · POSTED

Percentage of Participants With a Minimal Residual Disease Negative Complete Response (MRD[-]CR) as Assessed by the IRC

→

outcome · POSTED

Number of Participants With Treatment-emergent Adverse Events (TEAEs)

→

outcome · POSTED

Number of Participants Achieving MRD[-] Response

→

outcome · POSTED

Number of Participants With Sustained MRD[-]CR for at Least 12 Months as Assessed by the IRC

→

outcome · POSTED

Number of Participants With Sustained MRD[-]CR at Month 24 as Assessed by the IRC

→

outcome · POSTED

Kaplan-Meier Estimate of Duration of Response as Assessed by the IRC

→

outcome · POSTED

Time to Response as Assessed by the IRC

→

outcome · POSTED

Kaplan-Meier Estimate of Progression Free Survival (PFS) as Assessed by the IRC

→

outcome · POSTED

Kaplan-Meier Estimate of Overall Survival (OS)

→

outcome · POSTED

Number of Participants With Best Overall Confirmed Response of CR or Better as Assessed by the IRC

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria * Subject has provided informed consent prior to initiation of any study specific activities or procedures. * Male or female subjects age ≥ 18 years * First or second relapse of multiple myeloma by IMWG criteria (subjects refractory to the most recent line of therapy, excluding carfilzomib, are eligible) * Refractory to lenalidamide * Measurable disease with at least 1 of the following assessed within 28 days prior to enrollment: * IgG multiple myeloma: serum monoclonal protein (M-protein) level ≥ 1.0 g/dL * IgA, IgD, IgE multiple myeloma: serum M-protein level ≥ 0.5 g/dL * urine M-protein ≥ 200 mg per 24 hours * in subjects without measurable serum or urine M-protein, serum-free light chain (SFLC) ≥ 100 mg/L (involved light chain) and an abnormal serum kappa lambda ratio * Must have at least a PR to at least 1 line of prior therapy * Prior therapy with proteasome inhibitors is allowed. Subjects receiving prior carfilzomib therapy must have achieved at least a PR, was not removed due to toxicity, did not relapse within 60 days from discontinuation of carfilzomib, and must have at least a 6 month carfilzomib treatment-free interval from their last dose of carfilzomib * ECOG PS of 0 to 2 Exclusion Criteria * Primary refractory multiple myeloma * Waldenström macroglobulinemia * Multiple myeloma of IgM subtype * POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) * Plasma cell leukemia ( greater than 2.0 × 109/L circulating plasma cells by differential). If automated differential shows ≥ 20% of other cells, obtain manual differential to identify other cells. * Primary amyloidosis (patients with multiple myeloma with asymptomatic deposition of amyloid plaques found on biopsy would be eligible if all other criteria are met) * Previous diagnosis of amyloidosis associated with myeloma * Myelodysplastic syndrome * Toxicity requiring discontinuation of lenalidomide therapy * Prior treatment with pomalidomide
healthy Volunteers: false
maximum Age: 99 Years
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Carfilzomib, pomalidomide, and dexamethasone (KPd)
intervention Names
Drug: Carfilzomib
Drug: Dexamethasone
Drug: Pomalidomide
label
Carfilzomib combined with pomalidomide and dexamethasone
type
EXPERIMENTAL

interventions

arm Group Labels
Carfilzomib combined with pomalidomide and dexamethasone
description
Carfilzomib will be administered intravenously over 30 ± 5 minutes, on days 1, 8, and 15 (± 2 days) of each 28-day cycle for up to 12 cycles or progression. A dose of 20 mg/m\^2 will be administered on day 1 of cycle 1. All subsequent doses will be 56 mg/m\^2. The frequency of carfilzomib administration will be reduced to day 1 and 15 per cycle starting with cycle 13 and continued until progression or end of study.
name
Carfilzomib
other Names
Kyprolis
type
DRUG
arm Group Labels
Carfilzomib combined with pomalidomide and dexamethasone
description
Dexamethasone will be administered at least 30 minutes, but no more than 4 hours prior to carfilzomib on days of carfilzomib administration. Dexamethasone will be administered at a dose of 40 mg on days 1, 8, 15, and 22 of each 28-day cycle up to progression during cycles 1 to 12. Dexamethasone will be administered at a dose of 20 mg on days 1 and 15 of each 28-day cycle up to progression during cycles 13 onward. For subjects more than or equal to 75 years of age, the dose will be 20 mg during cycles 1 through 12 and 10 mg from cycles 13 onward.
name
Dexamethasone
other Names
Decadron, Ozurdex, DexPak 6, 10, 13 Day, ReadySHarp, LoCort, Maxidex
type
DRUG
arm Group Labels
Carfilzomib combined with pomalidomide and dexamethasone
description
Pomalidomide dose will be 4 mg per day orally on days 1 to 21 of each cycle until progression.
name
Pomalidomide
other Names
Pomalyst
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 54
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Overall response was defined as the best overall confirmed response of: Complete response (CR): Negative immunofixation on serum and urine, soft tissue plasmacytomas disappearance, \< 5% plasma cells in bone marrow (BM). Stringent CR (sCR): CR and normal serum free light chain ratio and no clonal cells in BM. Very Good Partial Response (VGPR): Serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein (urine M-protein level \< 100 mg/24-h). PR: ≥ 50% reduction of serum M-protein and 24-h urinary M-protein by ≥ 90% or to \< 200 mg/24-h. Assessment was by IRC per International Myeloma Working Group Uniform Response Criteria (IMWG-URC). The 90% confidence intervals were estimated using the Clopper-Pearson method (1994).
measure
Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC)
time Frame
From day 1 cycle 1 until the primary analysis (PA) data cutoff (DCO); the mean duration of KPd treatment as of the DCO was 42.0 weeks

secondary Outcomes

description
The MRD\[-\]CR rate was defined as the percentage of participants who reached MRD\[-\]CR at the 12 month landmark (8- to 13-month window). MRD\[-\]CR was defined as the achievement of CR (including sCR or better) per IMWG-URC by IRC assessment and MRD\[-\] status at a sensitivity of 10\^-5 using next-generation sequencing based method in the bone marrow. The 90% CIs were estimated using the Clopper-Pearson method (1994).
measure
Percentage of Participants With a Minimal Residual Disease Negative Complete Response (MRD[-]CR) as Assessed by the IRC
time Frame
Day 1 cycle 1 to month 12 (8 to 13 month window)
description
TEAEs were defined as events with onset on or after the administration of the first dose of any study treatment and within the end of study, or 30 days after the last dose of any study treatment, whichever one was earlier, excluding events reported after end of study date.
measure
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
time Frame
From the first dose of any study treatment until the end of study or 30 days after the last dose of any study treatment, whichever occured earlier; Median (min, max) was 8.5 (1.0, 46.6) months
description
MRD\[-\] response was defined as achievement of MRD\[-\] status using next generation sequencing (NGS) based method in the bone marrow at any time.
measure
Number of Participants Achieving MRD[-] Response
time Frame
From day 1 cycle 1 until the end of study (EOS); the mean duration of KPd treatment as of the EOS was 55.3 weeks
description
MRD\[-\]CR at the 12 months landmark was defined as achievement of CR (including sCR or better) per IMWG-URC by IRC and MRD\[-\] status at a sensitivity of 10\^-5 using NGS based method in the bone marrow at the 12 months landmark (from 8 months to 13 months window). Maintaining MRD\[-\]CR for at least 12 months (- 4 weeks) was considered as sustained.
measure
Number of Participants With Sustained MRD[-]CR for at Least 12 Months as Assessed by the IRC
time Frame
Day 1 cycle 1 to month 12 (8 to 13 month window)
description
Sustained MRD\[-\]CR at 24 months included participants that maintained MRD\[-\]CR for 12 months or more after achieving MRD\[-\]CR status at 12 months.
measure
Number of Participants With Sustained MRD[-]CR at Month 24 as Assessed by the IRC
time Frame
Day 1 cycle 1 to month 26 (19 to 26 month window)
description
Disease response and progression were determined using IMWG-URC. Durations were calculated for responders. Medians and percentiles were estimated using the Kaplan-Meier method. 90% CIs for medians and percentiles were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.
measure
Kaplan-Meier Estimate of Duration of Response as Assessed by the IRC
time Frame
From day 1 cycle 1 until the PA DCO; the mean duration of KPd treatment as of the DCO was 42.0 weeks
description
Durations were calculated for responders. Time to response was defined as the time from start of any study treatment date to the earliest date when confirmed sCR, CR, very good partial response (VGPR), or partial response (PR) was first achieved.
measure
Time to Response as Assessed by the IRC
time Frame
From day 1 cycle 1 until the PA DCO; the mean duration of KPd treatment as of the DCO was 42.0 weeks
description
PFS was defined as time from start of treatment until progression or death from any cause. Medians and percentiles were estimated using the Kaplan-Meier method by Klein and Moeschberger (1997). 90% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.
measure
Kaplan-Meier Estimate of Progression Free Survival (PFS) as Assessed by the IRC
time Frame
From day 1 cycle 1 until the PA DCO; the mean duration of KPd treatment as of the DCO was 42.0 weeks
description
OS was defined as the time from the start of treatment until death from any cause. Medians and percentiles were estimated using the Kaplan-Meier method. 90% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.
measure
Kaplan-Meier Estimate of Overall Survival (OS)
time Frame
From day 1 cycle 1 until the EOS; the mean duration of KPd treatment was 55.3 weeks.
description
The number of safety analysis set participants whose best overall response was sCR or CR per IMWG-URC over the duration of the study.
measure
Number of Participants With Best Overall Confirmed Response of CR or Better as Assessed by the IRC
time Frame
From day 1 cycle 1 until the PA DCO; the mean duration of KPd treatment as of the DCO was 42.0 weeks

Full study description

brief Summary: A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone
detailed Description: An Open-label, Phase 2 Study Treating Subjects with First or Second Relapse of Multiple Myeloma with Carfilzomib, Pomalidomide, and Dexamethasone (KPd) This trial is designed to estimate the efficacy of a carfilzomib-based triplet in first or second relapse of multiple myeloma for subjects refractory to lenalidomide. The study is an open-label, phase 2 trial. Subjects may receive treatment until progression. Myeloma disease status will be monitored locally for response and progression per International Myeloma Working Group (IMWG) criteria (Kumar et al, 2016) every 28 ± 7 days from cycle 1 day 1 until confirmed progressive disease (PD), death, lost to follow-up, or withdrawal of full consent (whichever occurs first), regardless of cycle duration, dose delays or treatment discontinuation. Subjects with a suspected complete response (CR) or better will have a bone marrow for minimal residual disease (MRD) assessment at 12 and 24 months (± 4 weeks) from start of treatment (unless a MRD assessment was performed within 4 months before planned assessment). Subjects who end study drug(s) without confirmed PD are required to complete disease response assessments and report new anti-myeloma treatment every 28 ± 7 days until first subsequent anti-myeloma treatment, death, lost to follow-up, withdrawal of full consent, confirmed PD, or end of study, whichever occurs first. Subjects who discontinue treatment and either start new anti-myeloma treatment or have PD will enter long-term follow-up every 12 weeks until death or end of study. Approximately one-third of subjects enrolled in the study will be in first relapse and two-thirds in second relapse. This study will enroll adults ≥ 18 years of age with first or second relapse multiple myeloma. Eligible subjects will have relapsed multiple myeloma after receiving 1 or 2 prior lines of therapy. Subjects must be refractory to lenalidomide. Subjects may not have received prior pomalidomide. Prior exposure to a proteasome inhibitor is allowed. Subjects previously exposed to carfilzomib must have responded with at least a partial response to carfilzomib, must not have discontinued carfilzomib due to toxicity, may not have relapsed while receiving or within 60 days of the last dose of carfilzomib, and must have at least a 6 month carfilzomib treatment-free interval since their last dose of carfilzomib. Subjects must have measurable disease per IMWG consensus criteria, Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2, and at least partial response to 1 line of therapy.

Source references

references

citation
Perrot A, Delimpasi S, Spanoudakis E, Frolund U, Belotti A, Oriol A, Moreau P, McFadden I, Xia Q, Arora M, Dimopoulos MA. An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leuk Lymphoma. 2024 Jun;65(6):833-842. doi: 10.1080/10428194.2024.2322030. Epub 2024 Mar 18.
pmid
38497533
type
BACKGROUND